Eledon Pharmaceuticals opened lower at $2.65, compared with its previous close of $2.67. In the last trading session, the stock traded between $2.38 and $2.65. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Eledon Pharmaceuticals is now worth
$ 47.76
Resulting in a loss of
$ 52.24 (52.24%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.31 (-11.46%)
Day High
$2.65
Day Low
$2.38
Day Open
$2.65
Prev Close
$2.67
Volume
7,51,195
1W Return
-12.28%
1M Return
-3.31%
3M Return
-36.88%
6M Return
-38.12%
1Y Return
10.99%
Market Cap ($ Mn)
192
PE Ratio
-
PB Ratio
7.83
PEG Ratio
-
ROE
-66.34%
ROCE
-31.86%
EPS (TTM)
$-0.37
1 Week
-12.28%
1 Month
-3.31%
3 Months
-36.88%
6 Months
-38.12%
9 Months
17.03%
Eledon Pharmaceuticals Q3FY27 Results: Loss narrows to $3.9M, EPS beats
Net loss narrowed to $3.9 million from $17.5 million YoY due to warrant gains. Adjusted loss per share of $(0.16) beat analyst estimates of $(0.19). R&D expenses rose 18.7% to $17.8 million ahead of Phase 3 trials. Cash balance stood at $69.7 million, funding operations into Q2 2027.
TodayEledon's tegoprubart gets FDA Fast Track for kidney transplant rejection
Eledon Pharmaceuticals' tegoprubart received FDA Fast Track designation for prevention of rejection in kidney transplantation. Phase 2 BESTOW data showed a 13 mL/min/1.73 m² eGFR advantage for tegoprubart over tacrolimus (71 vs. 58 mL/min/1.73 m²) at month 24. No BPAR cases occurred in the tegoprubart arm beyond six months post-transplant, versus seven in the tacrolimus arm. Phase 3 LEGACY trial, enrolling approximately 600 patients, is expected to initiate in Q4 2026.
1mo agoEledon Q2 EPS misses estimates as net loss widens 182% YoY
Eledon Pharmaceuticals reported a Q2 2026 net loss of $31.6 million ($0.27/share), missing the $(0.16) estimate by 68.75%. The loss widened 182% YoY due to a $9.6M non-cash warrant loss. Adjusted loss improved slightly to $22.0M. R&D fell 10% to $18.2M. Cash stands at $88.8M, funding operations into Q2 2027.
3mo agoNatera partners with Eledon for Phase 3 kidney trial
Natera has partnered with Eledon Pharmaceuticals to incorporate its Prospera kidney transplant assessment test into Eledon's planned Phase 3 clinical trial of Tegoprubart. The trial, targeting 600 patients globally, will use Prospera as the exclusive dd-cfDNA monitoring assay to detect early signs of rejection. Tegoprubart aims to improve graft protection while reducing toxicities associated with current immunosuppression therapies.
4mo agoEledon's tegoprubart shows superior kidney function in Phase 2 trial
Eledon Pharmaceuticals announced long-term data from its Phase 2 BESTOW trial showing tegoprubart maintained higher kidney function and zero late rejection events compared to tacrolimus. Patient-reported outcomes also favored tegoprubart, with fewer adverse events reported. The company plans to begin Phase 3 development in late 2026.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Eledon Pharmaceuticals is now worth
$ 47.76
Resulting in a loss of
$ 52.24 (52.24%)
Note: Past profits do not guarantee future returns.
